Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content | JCO Clinical Cancer Informatics
Optimizing Adjuvant Chemotherapy in Early-Stage Breast Cancer
Chemotherapy for Uterus Cancer
Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052) | Scientific Reports
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study ...
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial - The Lancet Regional Health – Western Pacific
Pregnancy-Associated Breast Cancer
Effect of Number of Treatment Cycles of Adjuvant Chemotherapy on Clinical Outcomes | Research To Practice
Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content | JCO Clinical Cancer Informatics
For the Patient: AC
PDF) Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer
Clatterbridge Centre for Oncology Chemotherapy Protocols
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content | JCO Clinical Cancer Informatics
HER2-Targeted Therapy for Early-Stage Breast Cancer: A Comprehensive Review
Efficacy of chemotherapy for lymph node-positive luminal A subtype breast cancer patients: an updated meta-analysis | World Journal of Surgical Oncology | Full Text
Chemotherapy Protocol
CONSORT diagram for Alliance/Cancer and Leukemia Group B 49907 trial.... | Download Scientific Diagram
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer -
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet
